of Solvay Biochemicals (Taixing) Limited (“SBT”) in 2017. 3. In 2018, the Company and its subsidiaries recorded loss on dilution on investment in Pimai Salt Company Limited amounting to 32 MB from the
(0) 2661-6664 2 INDORAMA VENTURES PUBLIC CO., LTD (SET: “IVL”) MANAGEMENT DISCUSSION AND ANALYSIS (MD&A) FOR THE YEAR ENDED DECEMBER 31, 2017 (CONSOLIDATED) Table 1: Financial Summary - Core Financials
(0) 2661-6664 2 INDORAMA VENTURES PUBLIC CO., LTD (SET: “IVL”) MANAGEMENT DISCUSSION AND ANALYSIS (MD&A) FOR THE YEAR ENDED DECEMBER 31, 2017 (CONSOLIDATED) Table 1: Financial Summary - Core Financials
targeting tourists and focusing on duty free shop distribution. Table 1 : Sales Revenue by Product Line for the Three Months Period Ended 30 June Product Line/ Business Group Consolidated financial statements
facial cleansing products gained most popularity from customers in the Philippines. Table 1: Sales Revenue by Product Line for the Three Months Period Ended 30 September Product Line/ Business Group
2019 Summary Financials Table 1: Core Financials of Consolidated Business Quarterly Last Twelve Months $million (except where stated otherwise) 3Q19 2Q19 3Q18 3Q19 YoY LTM 3Q19 LTM 3Q18 LTM YoY
the amount of 36.2 million Baht or 9.6 percent. For other income amounted 14.2 million Baht compared previously year 10.9 million Baht. Table below shows the share of revenues in 2017 comprised of
material decrease in sales from China. The Company has plans to expand further to other potential countries and is in the process of conducting market feasibility studies in those markets. Table 1: Sales
basis Attractive and accretive production pipeline heading into 2019 Indorama Ventures 2nd Quarter 2018 MD&A 2 2Q 2018 Summary Financials Table 1: Core Financials of Consolidated Business Quarterly Last
pipeline into 2019 Indorama Ventures 3rd Quarter 2018 MD&A 2 3Q 2018 Summary Financials Table 1: Core Financials of Consolidated Business Quarterly Last Twelve Months $m 3Q18 2Q18 3Q17 3Q18 YoY LTM 3Q18 LTM